Tredence, a global AI and data science solutions company, has announced the acquisition of KMK Consulting, a specialized analytics and consulting firm focused on the Life Sciences and Biopharma industry. The acquisition strengthens Tredence’s Healthcare & Life Sciences (HLS) capabilities and deepens its domain expertise across pharmaceutical commercial analytics, real-world evidence and market research.
Tredence has acquired KMK Consulting to expand its Life Sciences capabilities.
KMK works with 8 of the world’s top 10 pharmaceutical companies.
The deal strengthens Tredence’s Healthcare & Life Sciences (HLS) business strategy.
Combined expertise will enhance agentic AI applications across pharma value chains.
Tredence aims for HLS to contribute ~25% of future revenue.
The acquisition expands Tredence’s presence in the Veeva ecosystem.
The acquisition brings together KMK Consulting’s deep pharmaceutical domain expertise and Tredence’s advanced AI and data science capabilities. KMK has more than two decades of experience supporting global life sciences organizations, particularly in commercial analytics, real-world evidence (RWE) and market research.
By integrating these capabilities, Tredence aims to deliver more advanced AI-driven solutions tailored to the pharmaceutical industry’s most complex operational challenges.
A key focus of the combined entity will be accelerating agentic AI adoption across the life sciences value chain. This includes improving processes that are traditionally slow, manual and highly regulated, particularly across research, development and commercial operations.
The integration is expected to help pharmaceutical companies compress timelines from molecule development through to market launch, improving efficiency and unlocking new value creation opportunities across the sector.
The global market for AI in life sciences is projected to reach $69.3 billion by 2031, underscoring the strategic importance of this acquisition for Tredence’s long-term growth.
The combined capabilities position Tredence as an end-to-end AI partner across the molecule-to-market journey. KMK’s domain expertise complements Tredence’s strengths in applied AI, data engineering and decision intelligence, enabling more advanced solutions for pharmaceutical enterprises.
The acquisition also strengthens Tredence’s alignment with the Veeva ecosystem, a widely used cloud-based CRM and data platform in the life sciences industry that supports commercial operations, medical engagement and incentive compensation for pharmaceutical companies globally.
Shub Bhowmick, Co-Founder & CEO of Tredence, emphasized that domain expertise remains a key differentiator in AI transformation.
"While Tredence has consistently operated at the leading edge of AI and Data Science, our true differentiator has always been deep domain expertise. The acquisition of KMK reinforces this philosophy, bringing unparalleled strength in Pharmaceuticals and Life sciences. Together, we are accelerating our ambition to become a premier provider of AI solutions for this critical sector".
Michael Karbachinskiy, Founder & CEO of KMK Consulting, highlighted the synergy between both organizations.
"At KMK, our foundation has always been deep, long-standing expertise in Life sciences—understanding not just the science, but how it translates into real-world decisions and outcomes. With Tredence's strength in AI and Data Science, we now have the opportunity to amplify that expertise and deliver even greater impact to our clients."
Prashant Sareen, Head of Healthcare & Life Sciences at Tredence, emphasized the strategic expansion of capabilities across pharma operations.
"We have built a strong HLS foundation, helping global pharma companies accelerate R&D, modernize supply chains, and scale AI in production. KMK Consulting's domain depth is genuinely differentiated and, when combined with Tredence's, it enables us to deliver value in fundamentally new ways. This further advances everything we have been building in HLS"
Tredence’s acquisition of KMK Consulting reflects a broader strategy to expand its Healthcare & Life Sciences business into a significant revenue contributor. The company expects this segment to account for approximately 25% of total revenue over the medium term.
The combined organization will focus on accelerating AI adoption across pharma enterprises, particularly in areas where data-driven decision-making can significantly improve operational efficiency and commercial outcomes.
Tredence is a global AI and data science solutions provider focused on solving the last-mile problem in AI, the gap between insight creation and value realization. Tredence leverages deep domain expertise, data platforms and accelerators, and strategic partnerships to provide tailored, cutting-edge solutions to its clients. The company has 4,200+ employees across the San Francisco Bay Area, Chicago, Riyadh, London, Toronto, and Bengaluru, serving top brands in Retail, CPG, Hi-tech, Telecom, Healthcare, Travel, and Industrials.
